MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
71.22
+1.76 (+2.53%)
At close: 4:02PM EDT

71.60 +0.38 (0.53%)
After hours: 6:46PM EDT

Stock chart is not supported by your current browser
Previous close69.46
Open69.85
Bid70.30 x 800
Ask71.90 x 2900
Day's range69.75 - 71.31
52-week range52.83 - 72.89
Volume10,229,047
Avg. volume8,109,273
Market cap189.412B
Beta (3Y Monthly)0.98
PE ratio (TTM)146.85
EPS (TTM)0.49
Earnings date25 Oct 2018
Forward dividend & yield1.92 (2.75%)
Ex-dividend date2018-09-14
1y target est75.99
Trade prices are not sourced from all markets
  • Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
    Yahoo Finance2 hours ago

    Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional

    The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.

  • AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
    Zacks4 hours ago

    AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

    AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

  • What Nektar Therapeutics’ Valuation Trend Indicates
    Market Realist5 hours ago

    What Nektar Therapeutics’ Valuation Trend Indicates

    In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist5 hours ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.

  • Stocks making the biggest move premarket: MS, GS, UNH, JNJ, WMT & more
    CNBC12 hours ago

    Stocks making the biggest move premarket: MS, GS, UNH, JNJ, WMT & more

    These are the stocks posting the largest moves before the bell.

  • Business Wire13 hours ago

    U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer

    Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA

  • The Wall Street Journal15 hours ago

    [$$] European Corporate News Roundup

    A $900 million disposal by Spain’s Iberdrola and a revenue warning from British American Tobacco are the corporate highlights in Europe on Tuesday.

  • Merck’s Operating Expenditure and Recent Developments
    Market Realistyesterday

    Merck’s Operating Expenditure and Recent Developments

    Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.

  • Merck Is Expected to Record Steady Revenue Growth in Q3
    Market Realistyesterday

    Merck Is Expected to Record Steady Revenue Growth in Q3

    Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.

  • Novartis in Q3 2018: Analysts Expect Revenue Growth
    Market Realistyesterday

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.

  • This is Why Merck (MRK) is a Great Dividend Stock
    Zacksyesterday

    This is Why Merck (MRK) is a Great Dividend Stock

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • What Vertex Pharmaceuticals’ Valuation Trend Indicates
    Market Realist4 days ago

    What Vertex Pharmaceuticals’ Valuation Trend Indicates

    In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.

  • 3 Large-Cap Pharma Stocks Performing Better Than Industry
    Zacks4 days ago

    3 Large-Cap Pharma Stocks Performing Better Than Industry

    We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

  • Is This the Right Time to Enter Dow? 4 Great Picks
    Zacks4 days ago

    Is This the Right Time to Enter Dow? 4 Great Picks

    A glimpse at the 30-stock blue-chip index will reveal that the recent meltdown is likely to be transitory and can provide a good entry point for investors.